Cancer stem cells are an attractive target for immunotherapeutic approaches to glioblastoma. However, an immune inhibitory phenotype of cells currently classified as "glioma-initiating cells" (GIC) might counteract recognition by immune effector cells. Here, we investigate the contribution of the non-classical MHC molecule HLA-E to the immunosuppressive phenotype of GIC. HLA-E is expressed in GIC lines and its expression is reduced upon differentiation of GIC in serum-containing culture conditions. Constitutive HLA-E inhibits natural killer (NK) cell-mediated lysis of GIC since small-interfering RNA-mediated HLA-E gene silencing enhances the immunogenicity of GIC. Increased GIC lysis was observed both in the CD133+ and in the CD133− compartment. Furthermore, the use of interferon-γ as a possible agent to boost an immune response against glioblastoma cells might be limited by the concurrent upregulation of HLA-E.
Introduction
Considering the poor prognosis of patients with glioblastoma, there is a need for new therapies beyond surgery, radiotherapy and chemotherapy. Immunotherapy has been considered a promising alternative to treat this devastating disease. However, to date, the clinical results of immunotherapeutic strategies in glioblastoma have remained disappointing. This lack of efficacy might be related to immune inhibitory properties of glioblastoma cells facilitating immune evasion (Heimberger and Sampson, 2011) . Glioma cells should per se be prone to attack by immune effector cells since they express ligands for activating immune receptors on NK cells or cytotoxic T cells (Friese et al., 2003 (Friese et al., , 2004 Wischhusen et al., 2005; Eisele et al., 2006; Dietrich et al., 2011) . However, an immunosuppressive environment hampers an efficient immune response. The cytokine transforming growth factor (TGF)-β contributes largely to this local immunosuppression by multiple mechanisms, including upregulation of the inhibitory receptor CD94/NKG2A on immune effector cells (Bertone et al., 1999) . This heterodimeric receptor consisting of CD94 and either NKG2A or its splice variant NKG2C is expressed on the cell surface of NK cells as well as CD8+ αβ and γδ T cells (Pietra et al., 2009 ). The binding of CD94/NKG2A to its ligand, the atypical human leukocyte antigen (HLA)-E leads to phosphorylation of immunoreceptor tyrosine based inhibitory motifs (ITIMS) in the intracytoplasmatic domain of NKG2A and thus to inhibition of the lytic activity of NK cells. Conversely, the binding of CD94/NKG2C to HLA-E provides an activating signal, however NKG2C binds HLA-E with low affinity and is therefore thought to play a subordinate role (Wada et al., 2004) . Under physiological conditions, HLA-E is mainly involved in maternal immune tolerance. HLA-E is aberrantly expressed in several tumors such as lymphoma (Marin et al., 2003) , melanoma (Derre et al., 2006) , colon carcinoma (Bianchini et al., 2006) and ovarian cancer (Malmberg et al., 2002) and may contribute to immunosuppression in glioblastoma (Wischhusen et al., 2005; Mittelbronn et al., 2007) .
A crucial issue for effective cancer immunotherapy is the definition of the target. In this regard, a population of cells within glioblastomas with stem cell-like properties is of particular interest. GIC are defined by their stem cell properties of self-renewal, multipotency and tumorigenicity at low cell numbers in immunodeficient mice, forming tumors resembling the initial human tumors (Singh et al., 2004; Tabatabai and Weller, 2011) . In a hierarchical tumor model, GIC are supposed to have important functions in the initiation and maintenance of glioblastomas and therefore warrant being evaluated as a possible target for immunotherapy. GIC can be isolated from gliomas ex vivo and propagated under serum-free stem cell culture conditions including fibroblast and epidermal growth factor (Hemmati et al., 2003; Gunther et al., 2008) . Other approaches to isolate GIC use functional assays or cell surface markers such as CD133 (Tabatabai and Weller, 2011) . CD133, or prominin-1, a cholesterol binding molecule of unknown biological function, was initially introduced as a putative cell surface marker for GIC (Singh et al., 2004) and is still widely used. However, the role of CD133 in identifying GIC remains controversial Journal of Neuroimmunology 250 (2012) 27-34 
